Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

One of the most common types of cholesterol-lowering drugs is called statins. Some popular brands of statins include Lipitor ...

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

AstraZeneca, a pharmaceutical company, has announced its plans to bring a drug substance manufacturing facility to Virginia.

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in ...

A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.

Regulation of blood lipid levels is necessary for patients with cholelithiasis. Targeting PCSK9 and APOA4 may represent a promising approach for the prevention and treatment of cholelithiasis.

The PCSK9 inhibitor market is projected to experience substantial growth due to its use in statin-intolerant patients, emerging strategies for PCSK9 inhibition, its potential applications across ...

In a paper published in Science China Life Sciences, an Chinese research team present evidence to demonstrate that the upregulation of PCSK9 expression in endothelial cells of diabetic patients ...